COST-EFFECTIVENESS IN ENGLAND OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (ARCC) AFTER FAILURE OF PRIOR THERAPY

被引：2
|
作者：
Lister, J. [1 ]
Vataire, A. [2 ]
Amzal, B. [3 ]
Dinet, J. [2 ]
Meng, J. [1 ]
Karcher, H. [3 ]
Gabriel, S. [2 ]
机构：
[1] Analytica LASER, Lorrach, Germany
[2] Ipsen Pharma, Boulogne, France
[3] Analytica Laser, London, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.245
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN162
引用
收藏
页码：A441 / A441
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [42] Interim analysis of CASSIOPE: A real-world study of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy in Europe
    Procopio, G.
    Hamberg, P.
    Bigot, P.
    Suarez, C.
    Barthelemy, P.
    Eymard, J-C.
    Masini, C.
    Borau, P. Gajate
    Dutailly, P.
    Perrot, V.
    Staehler, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S571 - S571
  • [43] Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
    Wu, Bin
    Zhang, Qiang
    Sun, Jie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [44] Cost-Effectiveness in the Surgical Care of Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 177 - 179
  • [45] Cost-effectiveness of sunitinib in metastatic renal cell carcinoma
    Purmonen, Timo T.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2011, 11 (04) : 383 - 393
  • [46] Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
    Hoyle, Martin
    Green, Colin
    Thompson-Coon, Jo
    Liu, Zulian
    Welch, Karen
    Moxham, Tiffany
    Stein, Ken
    VALUE IN HEALTH, 2010, 13 (01) : 55 - 60
  • [47] Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
    Sarfaty, Michal
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    EUROPEAN UROLOGY, 2018, 73 (04) : 628 - 634
  • [48] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Powles, Thomas
    Motzer, Robert J.
    Escudier, Bernard
    Par, Sumanta
    Kollmannsberger, Christian
    Pikiel, Joanna
    Gurney, Howard
    Rha, Sun Young
    Park, Se Hoon
    Geertsen, Poul F.
    Gross-Goupil, Marine
    Grande, Enrique
    Suarez, Cristina
    Markby, David W.
    Arroyo, Alan
    Dean, Mark
    Choueiri, Toni K.
    George, Daniel
    BRITISH JOURNAL OF CANCER, 2018, 119 (06) : 663 - 669
  • [49] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Thomas Powles
    Robert J. Motzer
    Bernard Escudier
    Sumanta Pal
    Christian Kollmannsberger
    Joanna Pikiel
    Howard Gurney
    Sun Young Rha
    Se Hoon Park
    Poul F. Geertsen
    Marine Gross-Goupil
    Enrique Grande
    Cristina Suarez
    David W. Markby
    Alan Arroyo
    Mark Dean
    Toni K. Choueiri
    Daniel George
    British Journal of Cancer, 2018, 119 : 663 - 669
  • [50] Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma
    Janmaat, Vincent T.
    Bruno, Marco J.
    Polinder, Suzanne
    Lorenzen, Sylvie
    Lordick, Florian
    Peppelenbosch, Maikel P.
    Spaander, Manon C. W.
    PLOS ONE, 2016, 11 (04):
12345